Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
MitraClip REPAIR MR Study
The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: MitraClip™ device implantation
- procedure: Mitral Valve Repair Surgery
Eligibility
Inclusion Criteria:
1. Subject has severe (Grade III or greater per the ASE criteria, which includes severity
grades of 3+ and 4+) primary MR (mixed etiology is acceptable provided the principal
mechanism of action is a degenerative mitral valve) as assessed by the ECL.
2. The cardiac surgeon of the Site Heart Team (consisting of at least one
interventionalist, and one cardiac surgeon) has confirmed that the subject is a
candidate for mitral valve surgery and the EC have confirmed that the subject's mitral
valve anatomy is suitable for percutaneous repair with the MitraClip™ device with high
certainty of achieving MR ≤ mild
3. Subject is symptomatic (NYHA Class II/III/IV) or asymptomatic with LVEF ≤ 60%,
pulmonary artery systolic pressure > 50 mmHg, or LVESD > 40 mm
4. Subject is at moderate surgical risk defined as being at least 75 years of age at the
time of EC review. If younger than 75 years, then the subject should have:
1. Society of Thoracic Surgeons (STS) Predicted Risk of Mortality (PROM) Repair
Score ≥ 2%, OR
2. Presence of other comorbidities which may introduce a potential surgery-specific
impediment
5. Subject provides written informed consent
6. Subject is ≥ 18 years of age
Exclusion Criteria:
1. Subject is currently participating in another clinical investigation
2. Presence of other anatomic or comorbid conditions, or other medical, social, or
psychological conditions that, in the investigator's opinion, could limit the
subject's ability to participate in the clinical investigation or to comply with
follow-up requirements, or impact the scientific soundness of the clinical
investigation results.
3. Subject has ischemic or non-ischemic secondary MR
4. Concomitant severe tricuspid valve regurgitation
5. Ejection fraction <30%
6. Severe mitral annular calcification
7. Acute myocardial infarction in the past 12 weeks
8. Need for cardiac surgery to correct pulmonary valve disease, aortic valve disease, or
tricuspid valve disease
9. Subjects who have concurrent coronary artery disease that needs to be treated may be
included provided the subjects are eligible for both percutaneous coronary
intervention (PCI) and coronary artery bypass surgery. Subjects randomized to the
device group, must undergo PCI before the MitraClip™ device procedure. Subjects
randomized to the surgical (control) arm may undergo coronary artery revascularization
during mitral valve repair surgery
10. Surgical procedure performed in the past 30 days
11. Femoral vein cannot accommodate a 24 F catheter or presence of IVC filter would
interfere with the catheter or ipsilateral DVT
12. Transesophageal echocardiography (TEE) is contraindicated.
13. Hemodynamic instability: systolic pressure ≤ 90 mmHg without afterload reduction,
cardiogenic shock, or the need for inotropic support or IABP
14. Need for emergency surgery for any reason
15. Prior mitral valve surgery, valvuloplasty, mechanical prosthetic valve or VAD
16. Systolic anterior motion of the mitral valve
17. Hypertrophic cardiomyopathy
18. Renal insufficiency requiring dialysis
19. Active infections requiring current antibiotic therapy
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Tiffany Flores
650-725-8718
I'm interested
Psoriasis Clinical Trials
MitraClip REPAIR MR Study
The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: MitraClip™ device implantation
- procedure: Mitral Valve Repair Surgery
Eligibility
Inclusion Criteria:
1. Subject has severe (Grade III or greater per the ASE criteria, which includes severity
grades of 3+ and 4+) primary MR (mixed etiology is acceptable provided the principal
mechanism of action is a degenerative mitral valve) as assessed by the ECL.
2. The cardiac surgeon of the Site Heart Team (consisting of at least one
interventionalist, and one cardiac surgeon) has confirmed that the subject is a
candidate for mitral valve surgery and the EC have confirmed that the subject's mitral
valve anatomy is suitable for percutaneous repair with the MitraClip™ device with high
certainty of achieving MR ≤ mild
3. Subject is symptomatic (NYHA Class II/III/IV) or asymptomatic with LVEF ≤ 60%,
pulmonary artery systolic pressure > 50 mmHg, or LVESD > 40 mm
4. Subject is at moderate surgical risk defined as being at least 75 years of age at the
time of EC review. If younger than 75 years, then the subject should have:
1. Society of Thoracic Surgeons (STS) Predicted Risk of Mortality (PROM) Repair
Score ≥ 2%, OR
2. Presence of other comorbidities which may introduce a potential surgery-specific
impediment
5. Subject provides written informed consent
6. Subject is ≥ 18 years of age
Exclusion Criteria:
1. Subject is currently participating in another clinical investigation
2. Presence of other anatomic or comorbid conditions, or other medical, social, or
psychological conditions that, in the investigator's opinion, could limit the
subject's ability to participate in the clinical investigation or to comply with
follow-up requirements, or impact the scientific soundness of the clinical
investigation results.
3. Subject has ischemic or non-ischemic secondary MR
4. Concomitant severe tricuspid valve regurgitation
5. Ejection fraction <30%
6. Severe mitral annular calcification
7. Acute myocardial infarction in the past 12 weeks
8. Need for cardiac surgery to correct pulmonary valve disease, aortic valve disease, or
tricuspid valve disease
9. Subjects who have concurrent coronary artery disease that needs to be treated may be
included provided the subjects are eligible for both percutaneous coronary
intervention (PCI) and coronary artery bypass surgery. Subjects randomized to the
device group, must undergo PCI before the MitraClip™ device procedure. Subjects
randomized to the surgical (control) arm may undergo coronary artery revascularization
during mitral valve repair surgery
10. Surgical procedure performed in the past 30 days
11. Femoral vein cannot accommodate a 24 F catheter or presence of IVC filter would
interfere with the catheter or ipsilateral DVT
12. Transesophageal echocardiography (TEE) is contraindicated.
13. Hemodynamic instability: systolic pressure ≤ 90 mmHg without afterload reduction,
cardiogenic shock, or the need for inotropic support or IABP
14. Need for emergency surgery for any reason
15. Prior mitral valve surgery, valvuloplasty, mechanical prosthetic valve or VAD
16. Systolic anterior motion of the mitral valve
17. Hypertrophic cardiomyopathy
18. Renal insufficiency requiring dialysis
19. Active infections requiring current antibiotic therapy
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Tiffany Flores
650-725-8718
I'm interested
Dermatology Clinical Trials
MitraClip REPAIR MR Study
The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: MitraClip™ device implantation
- procedure: Mitral Valve Repair Surgery
Eligibility
Inclusion Criteria:
1. Subject has severe (Grade III or greater per the ASE criteria, which includes severity
grades of 3+ and 4+) primary MR (mixed etiology is acceptable provided the principal
mechanism of action is a degenerative mitral valve) as assessed by the ECL.
2. The cardiac surgeon of the Site Heart Team (consisting of at least one
interventionalist, and one cardiac surgeon) has confirmed that the subject is a
candidate for mitral valve surgery and the EC have confirmed that the subject's mitral
valve anatomy is suitable for percutaneous repair with the MitraClip™ device with high
certainty of achieving MR ≤ mild
3. Subject is symptomatic (NYHA Class II/III/IV) or asymptomatic with LVEF ≤ 60%,
pulmonary artery systolic pressure > 50 mmHg, or LVESD > 40 mm
4. Subject is at moderate surgical risk defined as being at least 75 years of age at the
time of EC review. If younger than 75 years, then the subject should have:
1. Society of Thoracic Surgeons (STS) Predicted Risk of Mortality (PROM) Repair
Score ≥ 2%, OR
2. Presence of other comorbidities which may introduce a potential surgery-specific
impediment
5. Subject provides written informed consent
6. Subject is ≥ 18 years of age
Exclusion Criteria:
1. Subject is currently participating in another clinical investigation
2. Presence of other anatomic or comorbid conditions, or other medical, social, or
psychological conditions that, in the investigator's opinion, could limit the
subject's ability to participate in the clinical investigation or to comply with
follow-up requirements, or impact the scientific soundness of the clinical
investigation results.
3. Subject has ischemic or non-ischemic secondary MR
4. Concomitant severe tricuspid valve regurgitation
5. Ejection fraction <30%
6. Severe mitral annular calcification
7. Acute myocardial infarction in the past 12 weeks
8. Need for cardiac surgery to correct pulmonary valve disease, aortic valve disease, or
tricuspid valve disease
9. Subjects who have concurrent coronary artery disease that needs to be treated may be
included provided the subjects are eligible for both percutaneous coronary
intervention (PCI) and coronary artery bypass surgery. Subjects randomized to the
device group, must undergo PCI before the MitraClip™ device procedure. Subjects
randomized to the surgical (control) arm may undergo coronary artery revascularization
during mitral valve repair surgery
10. Surgical procedure performed in the past 30 days
11. Femoral vein cannot accommodate a 24 F catheter or presence of IVC filter would
interfere with the catheter or ipsilateral DVT
12. Transesophageal echocardiography (TEE) is contraindicated.
13. Hemodynamic instability: systolic pressure ≤ 90 mmHg without afterload reduction,
cardiogenic shock, or the need for inotropic support or IABP
14. Need for emergency surgery for any reason
15. Prior mitral valve surgery, valvuloplasty, mechanical prosthetic valve or VAD
16. Systolic anterior motion of the mitral valve
17. Hypertrophic cardiomyopathy
18. Renal insufficiency requiring dialysis
19. Active infections requiring current antibiotic therapy
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Tiffany Flores
650-725-8718
I'm interested
Pediatric Dermatology Clinical Trials
MitraClip REPAIR MR Study
The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: MitraClip™ device implantation
- procedure: Mitral Valve Repair Surgery
Eligibility
Inclusion Criteria:
1. Subject has severe (Grade III or greater per the ASE criteria, which includes severity
grades of 3+ and 4+) primary MR (mixed etiology is acceptable provided the principal
mechanism of action is a degenerative mitral valve) as assessed by the ECL.
2. The cardiac surgeon of the Site Heart Team (consisting of at least one
interventionalist, and one cardiac surgeon) has confirmed that the subject is a
candidate for mitral valve surgery and the EC have confirmed that the subject's mitral
valve anatomy is suitable for percutaneous repair with the MitraClip™ device with high
certainty of achieving MR ≤ mild
3. Subject is symptomatic (NYHA Class II/III/IV) or asymptomatic with LVEF ≤ 60%,
pulmonary artery systolic pressure > 50 mmHg, or LVESD > 40 mm
4. Subject is at moderate surgical risk defined as being at least 75 years of age at the
time of EC review. If younger than 75 years, then the subject should have:
1. Society of Thoracic Surgeons (STS) Predicted Risk of Mortality (PROM) Repair
Score ≥ 2%, OR
2. Presence of other comorbidities which may introduce a potential surgery-specific
impediment
5. Subject provides written informed consent
6. Subject is ≥ 18 years of age
Exclusion Criteria:
1. Subject is currently participating in another clinical investigation
2. Presence of other anatomic or comorbid conditions, or other medical, social, or
psychological conditions that, in the investigator's opinion, could limit the
subject's ability to participate in the clinical investigation or to comply with
follow-up requirements, or impact the scientific soundness of the clinical
investigation results.
3. Subject has ischemic or non-ischemic secondary MR
4. Concomitant severe tricuspid valve regurgitation
5. Ejection fraction <30%
6. Severe mitral annular calcification
7. Acute myocardial infarction in the past 12 weeks
8. Need for cardiac surgery to correct pulmonary valve disease, aortic valve disease, or
tricuspid valve disease
9. Subjects who have concurrent coronary artery disease that needs to be treated may be
included provided the subjects are eligible for both percutaneous coronary
intervention (PCI) and coronary artery bypass surgery. Subjects randomized to the
device group, must undergo PCI before the MitraClip™ device procedure. Subjects
randomized to the surgical (control) arm may undergo coronary artery revascularization
during mitral valve repair surgery
10. Surgical procedure performed in the past 30 days
11. Femoral vein cannot accommodate a 24 F catheter or presence of IVC filter would
interfere with the catheter or ipsilateral DVT
12. Transesophageal echocardiography (TEE) is contraindicated.
13. Hemodynamic instability: systolic pressure ≤ 90 mmHg without afterload reduction,
cardiogenic shock, or the need for inotropic support or IABP
14. Need for emergency surgery for any reason
15. Prior mitral valve surgery, valvuloplasty, mechanical prosthetic valve or VAD
16. Systolic anterior motion of the mitral valve
17. Hypertrophic cardiomyopathy
18. Renal insufficiency requiring dialysis
19. Active infections requiring current antibiotic therapy
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Tiffany Flores
650-725-8718
I'm interested
MitraClip REPAIR MR Study
The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: MitraClip™ device implantation
- procedure: Mitral Valve Repair Surgery
Eligibility
Inclusion Criteria:
1. Subject has severe (Grade III or greater per the ASE criteria, which includes severity
grades of 3+ and 4+) primary MR (mixed etiology is acceptable provided the principal
mechanism of action is a degenerative mitral valve) as assessed by the ECL.
2. The cardiac surgeon of the Site Heart Team (consisting of at least one
interventionalist, and one cardiac surgeon) has confirmed that the subject is a
candidate for mitral valve surgery and the EC have confirmed that the subject's mitral
valve anatomy is suitable for percutaneous repair with the MitraClip™ device with high
certainty of achieving MR ≤ mild
3. Subject is symptomatic (NYHA Class II/III/IV) or asymptomatic with LVEF ≤ 60%,
pulmonary artery systolic pressure > 50 mmHg, or LVESD > 40 mm
4. Subject is at moderate surgical risk defined as being at least 75 years of age at the
time of EC review. If younger than 75 years, then the subject should have:
1. Society of Thoracic Surgeons (STS) Predicted Risk of Mortality (PROM) Repair
Score ≥ 2%, OR
2. Presence of other comorbidities which may introduce a potential surgery-specific
impediment
5. Subject provides written informed consent
6. Subject is ≥ 18 years of age
Exclusion Criteria:
1. Subject is currently participating in another clinical investigation
2. Presence of other anatomic or comorbid conditions, or other medical, social, or
psychological conditions that, in the investigator's opinion, could limit the
subject's ability to participate in the clinical investigation or to comply with
follow-up requirements, or impact the scientific soundness of the clinical
investigation results.
3. Subject has ischemic or non-ischemic secondary MR
4. Concomitant severe tricuspid valve regurgitation
5. Ejection fraction <30%
6. Severe mitral annular calcification
7. Acute myocardial infarction in the past 12 weeks
8. Need for cardiac surgery to correct pulmonary valve disease, aortic valve disease, or
tricuspid valve disease
9. Subjects who have concurrent coronary artery disease that needs to be treated may be
included provided the subjects are eligible for both percutaneous coronary
intervention (PCI) and coronary artery bypass surgery. Subjects randomized to the
device group, must undergo PCI before the MitraClip™ device procedure. Subjects
randomized to the surgical (control) arm may undergo coronary artery revascularization
during mitral valve repair surgery
10. Surgical procedure performed in the past 30 days
11. Femoral vein cannot accommodate a 24 F catheter or presence of IVC filter would
interfere with the catheter or ipsilateral DVT
12. Transesophageal echocardiography (TEE) is contraindicated.
13. Hemodynamic instability: systolic pressure ≤ 90 mmHg without afterload reduction,
cardiogenic shock, or the need for inotropic support or IABP
14. Need for emergency surgery for any reason
15. Prior mitral valve surgery, valvuloplasty, mechanical prosthetic valve or VAD
16. Systolic anterior motion of the mitral valve
17. Hypertrophic cardiomyopathy
18. Renal insufficiency requiring dialysis
19. Active infections requiring current antibiotic therapy
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Tiffany Flores
650-725-8718
I'm interested
MitraClip REPAIR MR Study
The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: MitraClip™ device implantation
- procedure: Mitral Valve Repair Surgery
Eligibility
Inclusion Criteria:
1. Subject has severe (Grade III or greater per the ASE criteria, which includes severity
grades of 3+ and 4+) primary MR (mixed etiology is acceptable provided the principal
mechanism of action is a degenerative mitral valve) as assessed by the ECL.
2. The cardiac surgeon of the Site Heart Team (consisting of at least one
interventionalist, and one cardiac surgeon) has confirmed that the subject is a
candidate for mitral valve surgery and the EC have confirmed that the subject's mitral
valve anatomy is suitable for percutaneous repair with the MitraClip™ device with high
certainty of achieving MR ≤ mild
3. Subject is symptomatic (NYHA Class II/III/IV) or asymptomatic with LVEF ≤ 60%,
pulmonary artery systolic pressure > 50 mmHg, or LVESD > 40 mm
4. Subject is at moderate surgical risk defined as being at least 75 years of age at the
time of EC review. If younger than 75 years, then the subject should have:
1. Society of Thoracic Surgeons (STS) Predicted Risk of Mortality (PROM) Repair
Score ≥ 2%, OR
2. Presence of other comorbidities which may introduce a potential surgery-specific
impediment
5. Subject provides written informed consent
6. Subject is ≥ 18 years of age
Exclusion Criteria:
1. Subject is currently participating in another clinical investigation
2. Presence of other anatomic or comorbid conditions, or other medical, social, or
psychological conditions that, in the investigator's opinion, could limit the
subject's ability to participate in the clinical investigation or to comply with
follow-up requirements, or impact the scientific soundness of the clinical
investigation results.
3. Subject has ischemic or non-ischemic secondary MR
4. Concomitant severe tricuspid valve regurgitation
5. Ejection fraction <30%
6. Severe mitral annular calcification
7. Acute myocardial infarction in the past 12 weeks
8. Need for cardiac surgery to correct pulmonary valve disease, aortic valve disease, or
tricuspid valve disease
9. Subjects who have concurrent coronary artery disease that needs to be treated may be
included provided the subjects are eligible for both percutaneous coronary
intervention (PCI) and coronary artery bypass surgery. Subjects randomized to the
device group, must undergo PCI before the MitraClip™ device procedure. Subjects
randomized to the surgical (control) arm may undergo coronary artery revascularization
during mitral valve repair surgery
10. Surgical procedure performed in the past 30 days
11. Femoral vein cannot accommodate a 24 F catheter or presence of IVC filter would
interfere with the catheter or ipsilateral DVT
12. Transesophageal echocardiography (TEE) is contraindicated.
13. Hemodynamic instability: systolic pressure ≤ 90 mmHg without afterload reduction,
cardiogenic shock, or the need for inotropic support or IABP
14. Need for emergency surgery for any reason
15. Prior mitral valve surgery, valvuloplasty, mechanical prosthetic valve or VAD
16. Systolic anterior motion of the mitral valve
17. Hypertrophic cardiomyopathy
18. Renal insufficiency requiring dialysis
19. Active infections requiring current antibiotic therapy
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Tiffany Flores
650-725-8718
I'm interested